Company Filing History:
Years Active: 1995-1999
Title: Richard D Swerdlow: Innovator in Bladder Cancer Treatment
Introduction
Richard D Swerdlow is a notable inventor based in Silver Spring, MD (US). He has made significant contributions to the field of immunotherapy, particularly in the treatment of bladder cancer. With a total of 3 patents, Swerdlow's work focuses on enhancing the efficacy of keyhole limpet hemocyanin (KLH) compositions.
Latest Patents
Swerdlow's latest patents include a method for treating bladder cancer using a stabilized KLH composition. This invention emphasizes the importance of maintaining the integrity of KLH, ensuring that its intact non-degraded subunit is approximately 400,000 in molecular weight. The composition is designed to contain at least 50% didecameric or higher KLH multimers, which are crucial for its immunogenic activity. The KLH composition is stabilized at 4°C in an isotonic buffer containing calcium and magnesium, and it is critical that the KLH is neither frozen nor lyophilized during preparation or storage. This innovative approach demonstrates enhanced anti-tumor activity, particularly in murine bladder tumor models, making it a promising candidate for anti-tumor immunotherapy.
Career Highlights
Throughout his career, Richard D Swerdlow has worked with various companies, including Per Immune Holdings, Inc. and Akzo N.V. His experience in these organizations has contributed to his expertise in developing immunotherapeutic agents.
Collaborations
One of his notable collaborators is Ray F Ebert, with whom he has worked on advancing the field of immunotherapy.
Conclusion
Richard D Swerdlow's innovative work in the development of KLH compositions for bladder cancer treatment highlights his significant contributions to medical science. His patents reflect a commitment to improving therapeutic options for patients, showcasing the potential of immunotherapy in cancer treatment.